Pharmacogenomics Testing - MEDICAID - VIRGINIA

This policy addresses pharmacogenomic/pharmacogenetic testing — including multi‑gene SNP panels, CYP2D6 deletion/duplication analysis, TPMT/NUDT15 genotyping, and gene-expression assays — to guide drug selection and dosing in oncology (e.g., ALL/thiopurine management), psychiatric disorders, pain/opioid prescribing (including pediatric codeine/tramadol), and opioid use disorder. The excerpt lists specific test descriptors, CPT codes and specimen types and cites guideline-based indications, but does not provide explicit coverage determinations, medical necessity criteria, age/frequency limits, or prior‑authorization requirements.

"No explicit statement of non-coverage for any of the referenced tests is present in this text chunk."

Sign up to see full coverage criteria, indications, and limitations.